Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement

Brian Han; Raul Montiel-Esparza; Henry Chubb; Saraswati Kache; Liora M Schultz; Kara L Davis; Sneha Ramakrishna; Lillian Su

doi:10.1016/j.jaccao.2020.08.009

Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement

JACC CardioOncol. 2020 Nov 17;2(4):666-670. doi: 10.1016/j.jaccao.2020.08.009. eCollection 2020 Nov.

Authors

Brian Han¹, Raul Montiel-Esparza², Henry Chubb¹, Saraswati Kache³, Liora M Schultz², Kara L Davis², Sneha Ramakrishna², Lillian Su¹

Affiliations

¹ Department of Pediatrics, Division of Cardiology, Lucile Packard Children's Hospital at Stanford, Stanford University Medical Center, Palo Alto, California, USA.
² Department of Pediatrics, Division of Hematology and Oncology, Lucile Packard Children's Hospital at Stanford, Stanford University Medical Center, Palo Alto, California, USA.
³ Department of Pediatrics, Division of Critical Care, Lucile Packard Children's Hospital at Stanford, Stanford University Medical Center, Palo Alto, California, USA.

No abstract available

Keywords: CAR T cell therapy; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; ICU, intensive care unit; LV, left ventricle; MRI, magnetic resonance imaging; PET, positron emission tomography; arrhythmia; cardiomyopathy; immunotherapy; leukemia.

Publication types

Review